Hey guys,
Anyone have info on sermorelin. I spoke to my guy about HGH, and he's recommended sermorelin. Says it will get my body to naturally produce HGH. I found some stuff on the net, but I can't tell if it's all hype. Real testimonials will go a long way.
Thanks in advance!
Muscleup
Here it is:
Sermorelin is a Gonadotropin-releasing hormone (GnRH) analog. "Official" name is GhRF 1-29 NH2-acetate.
I don't have any direct experience with it, but it was originally marketed for children with GH deficiency, including some of the GH-deficiency syndromes that I deal with in my clinical practice. It was withdrawn from the market by the manufacturer because it just couldn't compete with recombinant GH (rHGH).
Paradoxically, it failed in children for the very reason that makes it a better alternative for GH-replacement therapy (GHRT) in adults.
Its effects are regulated at the level of the pituitary gland, stimulating pituitary gene transcription of human growth hormone messenger RNA (hGHmRNA) and thereby increasing pituitary GH reserve. Pituitary recrudescence resulting from Sermorelin helps slow the cascade of hypophyseal hormone failure that occurs with normal aging. It's mode of action helps avoid some of the health concerns of rHGH. Most specifically, tissue exposure to GH released by the pituitary under the influence of sermorelin is "episodic," rather than so-called "square-wave." So what does this mean?
"Square-wave" release refers to what occurs with the pharmacologic presentation of exogenous hormone as a bolus (i.e. one good shot in the old thigh), and is not controlled by normal feedback mechanisms--therefore when one injects standard Chinese-made GH, tissue exposure to elevated GH concentrations is persistent and eventually may lead to tachyphylaxis and reduced efficiency. "Episodic" release prevents tachyphylaxis by mimicking more normal pulsatile release and physiology.
And now for the kicker for anti-aging clinics: Unlike GH, the off-label prescribing of sermorelin is not (yet ) prohibited by federal law.
